Fate Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Fate Therapeutics

05/05/2025 23:27

Fate Therapeutics Inc FATE.OQ FATE.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The San Diego California-based  company is expected to report a 40.7% decrease in revenue to $1.142 million from $1.93 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Fate Therapeutics Inc is for a loss of 38 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 3.6% in the last three months. ​

Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.00​, above​ its last closing price of $1.17. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.43
-0.43
-0.44
Missed
-1.7
Sep. 30 2024
-0.41
-0.43
-0.40
Beat
7.5
Jun. 30 2024
-0.47
-0.48
-0.33
Beat
30.6​
Mar. 31 2024
-0.48
-0.49
-0.47
Beat
3.8
​​Dec. 31 2023
-0.53
-0.52
-0.45
Beat
13.9
Sep. 30 2023
-0.56
-0.57
-0.46
Beat
19.3​
Jun. 30 2023
-0.58
-0.59
-0.54
Beat
8.2
Mar. 31 2023
-0.64
-0.62
-0.19
Beat
69.5

This summary was machine generated May 5 at 22:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)